Literature DB >> 8492861

Striatal glucose metabolism and [18F]fluorodopa uptake in a patient with tumor-induced hemiparkinsonism.

Y Miyagi1, T Morioka, M Otsuka, M Fukui.   

Abstract

We studied a patient with a falx meningioma in the right supplementary motor area and a left-sided hemiparkinsonism that resolved after the tumor was removed. Because there was no evidence of distortion of the basal ganglia and midbrain by the tumor on neuroradiological examination, the possible mechanism of parkinsonism is an impairment of the basal ganglia output to the supplementary motor area. Positron emission tomography scans with 2-[18F]fluoro-2-doxy-D-glucose and 6-L-[18F]fluorodopa were performed to measure regional cerebral glucose metabolism and striatal dopamine metabolism, respectively. Regional cerebral glucose metabolism was decreased in the striatum of the side of the lesion, although dopamine metabolism was normal. These data suggest that the tumor may have impaired synaptic function of the striatum as a whole, giving rise to contralateral hemiparkinsonism without an impairment of the presynaptic dopaminergic nerve terminals in the striatum.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492861     DOI: 10.1227/00006123-199305000-00019

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  3 in total

1.  Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia.

Authors:  J K Krauss; T Paduch; F Mundinger; W Seeger
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

2.  Parkisonism followed by burr hole drainage for chronic subdural hemorrhage.

Authors:  Cheng-Chia Lee; Chun-Fu Lin; Yang-Hsin Shih
Journal:  J Neurosci Rural Pract       Date:  2011-07

3.  Usefulness of F-18 FP-CIT PET to predict dopamine-responsive hand tremor in patients other than Parkinson's disease: Two case reports.

Authors:  Kwang Jae Yu; Byung Joo Lee; Jin Han; Donghwi Park
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.